European Medical Solutions S.à r.l. | Small-cap | Healthcare
€4.70
2.16%
| European Medical Stock Comparison:
European Medical vs Argenx SEEuropean Medical vs UCB S.AEuropean Medical vs Celyad Oncology S.AEuropean Medical vs Biosenic SAEuropean Medical vs Oxurion NVEuropean Medical vs BEL 20 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 48.5M
Total Liabilities 38.1M
Shareholders Equity 10.3M
Debt to Equity 3.69

Cash Flow Metrics

Revenue & Profitability Trend

European Medical Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i45.1M40.6M35.3M36.3M0
Cost of Goods Sold i30.2M27.1M23.0M24.2M-
Gross Profit i15.0M13.5M12.3M12.1M-
Gross Margin % i33.1%33.3%34.7%33.2%0.0%
Operating Expenses
Research & Development i02.0K40.0K0-53.0K
Selling, General & Administrative i595.0K520.0K647.0K423.0K478.0K
Other Operating Expenses i6.3M5.6M5.9M5.3M-312.5K
Total Operating Expenses i6.9M6.1M6.6M5.7M112.5K
Operating Income i1.4M18.0K-1.6M28.0K-676.5K
Operating Margin % i3.1%0.0%-4.7%0.1%0.0%
Non-Operating Items
Interest Income i284.0K85.0K3.0K-74.0K
Interest Expense i686.0K432.0K237.0K200.0K503.0K
Other Non-Operating Income-----
Pre-tax Income i751.0K-710.0K-5.6M-242.0K-1.4M
Income Tax i205.0K2.0K-1.0K-1.0K0
Effective Tax Rate % i27.3%0.0%0.0%0.0%0.0%
Net Income i546.0K-712.0K-5.6M-241.0K-1.4M
Net Margin % i1.2%-1.8%-15.8%-0.7%0.0%
Key Metrics
EBITDA i3.8M2.0M2.3M2.0M-450.8K
EPS (Basic) i-€-0.18€-1.30€-3.52€-21.12
EPS (Diluted) i-€-0.18€-1.30€-3.52€-21.12
Basic Shares Outstanding i-423183942318396846662194
Diluted Shares Outstanding i-423183942318396846662194

Income Statement Trend

European Medical Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i4.6M4.2M4.2M2.4M2.9M
Short-term Investments i711.0K959.0K409.0K--
Accounts Receivable i7.3M5.2M6.0M6.5M-
Inventory i13.0M14.4M13.0M11.6M-
Other Current Assets6.6M3.7M1.3M811.0K1.0K
Total Current Assets i34.2M30.8M27.5M24.0M3.1M
Non-Current Assets
Property, Plant & Equipment i6.0M6.0M5.8M5.9M129.0K
Goodwill i9.6M7.6M6.7M6.3M-
Intangible Assets i9.6M7.6M6.7M6.3M-
Long-term Investments-----
Other Non-Current Assets----1.0K
Total Non-Current Assets i14.3M12.9M12.4M12.3M2.0M
Total Assets i48.5M43.8M39.9M36.3M5.1M
Liabilities
Current Liabilities
Accounts Payable i10.3M9.3M6.6M6.6M4.2M
Short-term Debt i8.4M6.1M4.4M4.3M5.3M
Current Portion of Long-term Debt-----
Other Current Liabilities2.3M2.4M2.8M333.0K90.0K
Total Current Liabilities i21.3M19.0M17.6M15.4M10.4M
Non-Current Liabilities
Long-term Debt i12.5M13.1M10.9M9.2M0
Deferred Tax Liabilities i00---
Other Non-Current Liabilities1.0K-2.0K2.0K2.0K274.0K
Total Non-Current Liabilities i16.8M14.9M11.6M10.1M406.0K
Total Liabilities i38.1M33.9M29.3M25.4M10.8M
Equity
Common Stock i66.1M66.1M66.1M4.6M17.1M
Retained Earnings i547.0K-712.0K-5.6M-214.0K-60.0M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i10.3M9.9M10.6M10.9M-5.6M
Key Metrics
Total Debt i20.9M19.1M15.3M13.5M5.3M
Working Capital i12.9M11.9M9.9M8.6M-7.3M

Balance Sheet Composition

European Medical Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i547.0K-712.0K-5.6M-241.0K-1.4M
Depreciation & Amortization i-----
Stock-Based Compensation i---14.0K-97.0K
Working Capital Changes i-1.5M-3.4M-1.1M-2.1M-1.1M
Operating Cash Flow i-483.0K-4.1M-3.7M-7.0M-2.1M
Investing Activities
Capital Expenditures i-3.5M-2.6M-2.2M-1.9M175.0K
Acquisitions i-----
Investment Purchases i-----
Investment Sales i---47.0K0
Investing Cash Flow i-2.9M-1.5M-992.0K-1.3M638.0K
Financing Activities
Share Repurchases i-----
Dividends Paid i----521.0K-
Debt Issuance i3.6M5.4M3.0M3.5M-
Debt Repayment i-2.2M-1.7M-2.4M-960.0K-
Financing Cash Flow i1.4M3.7M706.0K2.0M-
Free Cash Flow i-1.0M-4.8M-117.0K-1.6M-1.4M
Net Change in Cash i-2.0M-1.9M-4.0M-6.4M-1.4M

Cash Flow Trend

European Medical Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 35.38
Price to Book 1.88
Price to Sales 0.41

Profitability Ratios

Profit Margin 1.14%
Operating Margin 3.24%
Return on Equity 5.40%
Return on Assets 1.70%

Financial Health

Current Ratio 1.53
Debt to Equity 191.98
Beta 0.52

Per Share Data

EPS (TTM) €0.13
Book Value per Share €2.44
Revenue per Share €11.32

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
alems19.5M35.381.885.40%1.14%191.98
Argenx SE 36.2B33.975.7824.72%41.03%0.71
UCB S.A 35.1B26.903.6214.30%19.45%29.72
Celyad Oncology S.A 16.2M-0.2232.50-170.92%0.00%177.10
Biosenic SA 1.6M0.00-126.75%-279.17%-1.18
Oxurion NV 1.5M0.00--1.08%3,966.67%-1.02

Financial data is updated regularly. All figures are in the company's reporting currency.